Expression and Potential Biomarkers of Regulators for M7G RNA Modification in Gliomas

Abstract

Gliomas are the most frequent primary malignant brain tumors of the central nervous system, causing significant impairment and death. There is mounting evidence that N7 methylguanosine (m7G) RNA dysmethylation plays a significant role in the development and progression of cancer. However, the expression patterns and function of the m7G RNA methylation regulator in gliomas are yet unknown. The goal of this study was to examine the expression patterns of 31 critical regulators linked with m7G RNA methylation and their prognostic significance in gliomas. To begin, we systematically analyzed patient clinical and prognostic data and mRNA gene expression data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. We found that 17 key regulators of m7G RNA methylation showed significantly higher expression levels in gliomas. We then divided the sample into two subgroups by consensus clustering. Cluster 2 had a poorer prognosis than cluster 1 and was associated with a higher histological grade. In addition, cluster 2 was significantly enriched for cancer-related pathways. Based on this discovery, we developed a risk model involving three m7G methylation regulators. Patients were divided into high-risk and low-risk groups based on risk scores. Overall survival (OS) was significantly lower in the high-risk group than in the low-risk group. Further analysis showed that the risk score was an independent prognostic factor for gliomas.

The Risk Correlation between N7-Methylguanosine Modification-Related lncRNAs and Survival Prognosis of Oral Squamous Cell Carcinoma Based on Comprehensive Bioinformatics Analysis

“…In addition, we conducted a comprehensive risk analysis for OSCC patients with highand low-risk groups and performed independent prognostic analyses and ROC curve analyses to verify the predictive performance of OSCC prognostic risk score model. However, there are still some limitations in this study, such as the lack of further studies on the important functions and key pathways of different pathological subtypes of OSCC and m7G-related gene [43]. More experimental validation of tissue samples from patients is needed in the future to further validate our new findings.…”

“…However, there are still some limitations in this study, such as the lack of further studies on the important functions and key pathways of different pathological subtypes of OSCC and m7G-related gene [ 43 ]. More experimental validation of tissue samples from patients is needed in the future to further validate our new findings.…”

Experimental verification and comprehensive analysis of m7G methylation regulators in the subcluster classification of ischemic stroke

“…Based on previous studies on m7G, 34 m7G key regulatory genes were included in this study as study objects, including DCP2, AGO2, CYFIP1, CYFIP2, DCPS, EIF3D, EIF4A1, EIF4E, EIF4E1B, EIF4E2, EIF4E3, EIF4G3, GEMIN5, IFIT5, LARP1, LSM1, METTL1, NCBP1, NCBP2, NCBP2L, NCBP3, NSUN2, NUDT1, NUDT10, NUDT11, NUDT16, NUDT16L1, NUDT3, NUDT4, NUDT4B, NUDT5, NUDT7, SNUPN, and WDR4 ( Tomikawa, 2018 ; Chen et al, 2022 ). Differences in the expression patterns of these genes between patients and controls were detected using the Wilcoxon test, with a selection criterion of p < 0.05.…”

The role of RNA modification in the generation of acquired drug resistance in glioma

“…Another study showed the potential role of m7G in gliomas. Chen et al (2022) found that 17 out of 31 regulators of m7G RNA methylation showed significantly higher expression levels in gliomas. Based on these 17 genes, they developed a risk model involving three m7G methylation regulators.…”